Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.82 Insider Own66.20% Shs Outstand27.86M Perf Week-14.48%
Market Cap22.87M Forward P/E- EPS next Y-0.50 Insider Trans0.00% Shs Float9.42M Perf Month-5.60%
Income-22.86M PEG- EPS next Q-0.20 Inst Own27.99% Short Float0.27% Perf Quarter-8.79%
Sales1.72M P/S13.30 EPS this Y17.82% Inst Trans0.31% Short Ratio0.72 Perf Half Y-27.35%
Book/sh1.17 P/B0.70 EPS next Y39.76% ROA-51.40% Short Interest0.03M Perf Year-72.72%
Cash/sh1.19 P/C0.69 EPS next 5Y- ROE-59.60% 52W Range0.63 - 4.05 Perf YTD-25.70%
Dividend Est.- P/FCF- EPS past 5Y11.01% ROI-67.67% 52W High-79.73% Beta1.54
Dividend TTM- Quick Ratio6.89 Sales past 5Y3540.46% Gross Margin- 52W Low30.09% ATR (14)0.08
Dividend Ex-Date- Current Ratio6.89 EPS Y/Y TTM-0.95% Oper. Margin-1453.95% RSI (14)46.05 Volatility9.60% 9.51%
Employees36 Debt/Eq0.05 Sales Y/Y TTM-62.91% Profit Margin-1329.13% Recom1.00 Target Price6.00
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q44.65% Payout- Rel Volume0.21 Prev Close0.86
Sales Surprise-49.89% EPS Surprise-48.39% Sales Q/Q-38.52% EarningsMay 20 BMO Avg Volume35.52K Price0.82
SMA20-6.84% SMA500.91% SMA200-24.74% Trades Volume7,634 Change-4.96%
Date Action Analyst Rating Change Price Target Change
Oct-21-22Resumed Jefferies Hold $5.50
Dec-31-19Reiterated JMP Securities Mkt Outperform $20 → $33
Dec-31-19Reiterated H.C. Wainwright Buy $23 → $26
Jul-15-24 07:00AM
May-28-24 07:00AM
May-20-24 01:53PM
06:00AM Loading…
May-16-24 06:00AM
Apr-01-24 07:00AM
Mar-13-24 07:00AM
Nov-30-23 07:00AM
Nov-28-23 08:06AM
Nov-09-23 07:00AM
Oct-31-23 06:43AM
Oct-30-23 10:05AM
Aug-30-23 08:00AM
Aug-10-23 08:15AM
07:00AM Loading…
Jul-21-23 06:04AM
Jun-06-23 07:30AM
Jun-02-23 06:09AM
May-12-23 08:25AM
Apr-22-23 08:19AM
Mar-22-23 05:43AM
Mar-20-23 07:00AM
Mar-15-23 11:44AM
Mar-12-23 08:23AM
Mar-10-23 08:15AM
Feb-27-23 06:02AM
Feb-23-23 02:32PM
07:29AM Loading…
Jan-27-23 07:29AM
Dec-08-22 06:16AM
Dec-07-22 10:52AM
Nov-10-22 04:00AM
Nov-03-22 03:03PM
Oct-03-22 08:00AM
Sep-19-22 01:00PM
Sep-12-22 04:30AM
Sep-09-22 12:13PM
Aug-04-22 06:00AM
Jun-01-22 08:00AM
May-27-22 11:45AM
May-17-22 07:00AM
May-13-22 07:00AM
Apr-25-22 07:00AM
Apr-14-22 08:30AM
Apr-12-22 11:26AM
Mar-30-22 07:00AM
Mar-25-22 11:00AM
Dec-22-21 04:05PM
Dec-21-21 07:00AM
Nov-30-21 08:27AM
Nov-11-21 07:00AM
Nov-09-21 07:05AM
Nov-04-21 07:30AM
Oct-01-21 12:14PM
Sep-22-21 07:30AM
Sep-09-21 08:30AM
Aug-17-21 01:30PM
Aug-04-21 07:05AM
Jul-27-21 10:26AM
Jul-20-21 07:05AM
Jun-28-21 05:10AM
May-27-21 07:00AM
May-18-21 09:27AM
May-13-21 07:05AM
Apr-28-21 08:41PM
Apr-27-21 02:20PM
Mar-19-21 06:56AM
Mar-10-21 10:29AM
Mar-04-21 07:05AM
Feb-24-21 07:05AM
Jan-18-21 07:49AM
Jan-11-21 07:05AM
Dec-07-20 07:05AM
Dec-01-20 08:33AM
Nov-18-20 12:08AM
Nov-16-20 01:25AM
Nov-12-20 08:21AM
Nov-09-20 07:05AM
Nov-04-20 04:05PM
Sep-28-20 02:34PM
Sep-10-20 04:01PM
Sep-08-20 07:05AM
Sep-03-20 07:05AM
Aug-06-20 07:08AM
Jul-29-20 07:05AM
Jul-28-20 08:27AM
Jun-29-20 07:00AM
Jun-16-20 04:05PM
Jun-04-20 05:28PM
May-27-20 09:00AM
May-14-20 07:05AM
May-07-20 04:05PM
Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.